305 related articles for article (PubMed ID: 33669809)
1. Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.
Ventura F; Williams E; Ikeya M; Bullock AN; Ten Dijke P; Goumans MJ; Sanchez-Duffhues G
Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33669809
[TBL] [Abstract][Full Text] [Related]
2. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
[TBL] [Abstract][Full Text] [Related]
3. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
4. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
[TBL] [Abstract][Full Text] [Related]
5. Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.
Sánchez-Duffhues G; Williams E; Benderitter P; Orlova V; van Wijhe M; Garcia de Vinuesa A; Kerr G; Caradec J; Lodder K; de Boer HC; Goumans MJ; Eekhoff EMW; Morales-Piga A; Bachiller-Corral J; Koolwijk P; Bullock AN; Hoflack J; Ten Dijke P
JBMR Plus; 2019 Nov; 3(11):e10230. PubMed ID: 31768489
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
7. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Lin H; Shi F; Gao J; Hua P
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
[TBL] [Abstract][Full Text] [Related]
8. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Luo Y; Alsamarah A; Zhang K; Hao J
Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
[TBL] [Abstract][Full Text] [Related]
9. Activation of G
Ebner JK; König GM; Kostenis E; Siegert P; Aktories K; Orth JHC
Bone; 2019 Oct; 127():592-601. PubMed ID: 31376533
[TBL] [Abstract][Full Text] [Related]
10. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
Katagiri T; Tsukamoto S; Kuratani M
Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
[TBL] [Abstract][Full Text] [Related]
12. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
[TBL] [Abstract][Full Text] [Related]
13. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
Sekimata K; Sato T; Sakai N
Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
[TBL] [Abstract][Full Text] [Related]
14. When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Groppe J; Shore EM
Drug Discov Today Ther Strateg; 2008; 5(4):255-262. PubMed ID: 23599718
[TBL] [Abstract][Full Text] [Related]
15. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
Ullrich T; Arista L; Weiler S; Teixeira-Fouchard S; Broennimann V; Stiefl N; Head V; Kramer I; Guth S
Bioorg Med Chem Lett; 2022 May; 64():128667. PubMed ID: 35276359
[TBL] [Abstract][Full Text] [Related]
17. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
Wang H; Shore EM; Pignolo RJ; Kaplan FS
Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
[TBL] [Abstract][Full Text] [Related]
18. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
[TBL] [Abstract][Full Text] [Related]
19. From mysteries to medicines: drug development for fibrodysplasia ossificans progressive.
Kaplan FS; Pignolo RJ; Shore EM
Expert Opin Orphan Drugs; 2013 Aug; 1(8):637-649. PubMed ID: 24800180
[TBL] [Abstract][Full Text] [Related]
20. Recent Topics in Fibrodysplasia Ossificans Progressiva.
Katagiri T; Tsukamoto S; Nakachi Y; Kuratani M
Endocrinol Metab (Seoul); 2018 Sep; 33(3):331-338. PubMed ID: 30229572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
